INNIO Signs Agreement with EGAT to Develop Advanced Microgrid Solutions in Thailand
INNIO announced today that it has signed a memorandum of understanding (MOU) with the Electricity Generating Authority of Thailand (EGAT) to support the development of a microgrid demonstration at EGAT’s proposed zero-emissions energy excellence center in Thailand. EGAT is planning to install a Jenbacher gas engine from INNIO that runs on 100% renewable gases such as biogas and green hydrogen and support the green microgrid demonstration. The MOU ceremony was held at the EGAT learning center in Bangkok.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191115005236/en/
From left to right: Tawatchai Sumranwanich (EGAT, Generation and Transmission System Planning Division), Patana Sangsriroujana (EGAT, Deputy Governor Strategy), Carlos Lange (INNIO, President & CEO) and Anand Anton (INNIO, General Manager Sales and Services APAC). Copyright: EGAT
New and improved technologies are helping power producers generate electricity with fewer carbon emissions and greater efficiency. EGAT has turned to such technologies to move towards the development of renewable energy innovation and away from fossil fuel energy to reach global climate goals, energy security and independence1.
“We are excited to work with INNIO on this project, as we develop a green microgrid demonstration project at EGAT. Our plans are to install that kind of solution across Thailand and possibly beyond,” said Patana Sangsriroujana, Deputy Governor - Strategy, EGAT.
The MOU with INNIO establishes a framework to define the utilization of advanced renewable energy sources and demonstrate a microgrid project at EGAT’s Learning Center in Bang Krui, Nonthaburi, Thailand, which is expected to be completed by the end of 2020. The integration of the Jenbacher gas engine with various other technologies — such as a battery system, wind and solar power and an electrolyzer system producing green hydrogen – will bring to Thailand a green microgrid that is sustainable, efficient and resilient, allowing for advanced energy management, demand response and load reduction solutions.
“EGAT’s zero-emissions energy excellence center in Thailand is expected to be a lighthouse project for the entire Southeast Asia region, and we are excited to be a part of this innovative venture,” said Carlos Lange, CEO & President, INNIO. “INNIO’s Jenbacher gas engines run on natural gas, or a variety of other gases, such as biogas and hydrogen. INNIO gas engines are deploying more than 68 gigawatts to a wide variety of industries, providing reliable, efficient and sustainable heat and power to help meet Thailand’s goals for energy security and independence.”
* Indicates a registered trademark
About The Electricity Generating Authority of Thailand (EGAT)
EGAT is a state enterprise under the Ministry of Energy responsible for electric power generation and transmission as well as bulk electric energy sales in Thailand, established on May 1, 1969. EGAT is the largest power utility in Thailand, owning and operating power plants at 45 sites across the country with a total installed capacity of 15,548 megawatts.
http://www.egat.co.th/en/.
About INNIO
INNIO is a leading solutions provider of gas engines, power equipment, a digital platform and related services for power generation and gas compression at or near the point of use. With our Jenbacher and Waukesha product brands, INNIO pushes beyond the possible and looks boldly toward tomorrow. Our diverse portfolio of reliable, economical and sustainable industrial gas engines generates 200 kW to 10 MW of power for numerous industries globally. We can provide life cycle support to the more than 50,000 delivered gas engines worldwide. And, backed by our service network in more than 100 countries, INNIO connects with you locally for rapid response to your service needs.
Headquartered in Jenbach, Austria, the business also has primary operations in Welland, Ontario, Canada, and Waukesha, Wisconsin, US. For more information, visit the company's website at www.innio.com. Follow INNIO on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191115005236/en/
Contact information
Susanne Reichelt
INNIO
+43 664 80833 2382
susanne.reichelt@ge.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment7.12.2019 19:00:00 CET | Press release
Kite, a Gilead Company (Nasdaq: GILD), today announced new data from the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. These results included updated overall survival data from the pivotal phase 2 study after three years following a single infusion of Yescarta, as well as an analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome (CRS) and neurologic events. The data were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, in Orlando from December 7–10, 2019. With a minimum follow-up of three years after a single infusion of Yescarta (median follow-up of 39.1 months), approximately half (n=47/101; 47 percent) of patients with refractory large B-cell lymphoma in ZUMA-1 pivotal phase 2 cohorts were alive, and the median overall survival (OS) was 25.8 months. These updated three-year survival data were presented a
Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma7.12.2019 15:20:00 CET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed or refractory multiple myeloma. The study enrolled patients who had received at least three prior lines of therapy or were double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); had received a PI, IMiD and an anti-CD38 antibody. The CARTITUDE-1 study results, premiered at the American Society of Hematology (ASH) Annual Meeting, were featured as an oral presentation and highlighted in the official ASH press programme (Abstract #577).1 Results from the Phase 1b portion of the CARTITUDE-1 study showed early and deep responses among patients (n=29) with a median of five prior multiple myeloma
Imbruvica®▼(ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukaemia7.12.2019 15:18:00 CET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL. Results from a 48-month follow-up analysis of the Phase 3 E1912 clinical study reported a statistically significant difference in PFS and OS for ibrutinib plus rituximab compared to a standard chemoimmunotherapy regimen of FCR.1 Further, the latest integrated analysis from the Phase 3 RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115/1116) studies investigating the use of single-agent ibrutinib in CLL, reported at up to six years of follow-up, PFS, OS and response rates improved when ibrutinib was used in earlier lines of therapy.2 During this extended follow-up, ibrutinib was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.2 In addition, results presented from the Phase 2 CAPTIVATE stu
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis7.12.2019 14:30:00 CET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving NINLARO plus dexamethasone versus physician’s choice (odds ratio 1.10 [95% CI 0.60-2.01], p=0.762) as assessed by an Adjudication Committee (AC). The second primary endpoint of two-year vital organ deterioration or death was not mature at the time of analysis. Other endpoints stu
Schlumberger Announces Fourth-Quarter and Full-Year 2019 Results Conference Call6.12.2019 18:07:00 CET | Press release
Schlumberger Limited (NYSE:SLB) will hold a conference call on January 17, 2020 to discuss the results for the fourth quarter and full year ending December 31, 2019. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 4013483. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 17, 2020, and can be accessed by dialing +1 (866) 207-1041 within North Amer
BUFF STUDIO Globally Launches My Coloring, a Mobile 3D Pixel Art Coloring Book Game6.12.2019 13:00:00 CET | Press release
BUFF STUDIO announced on December 5 that it launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191206005162/en/ BUFF STUDIO launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. My Coloring is a game that materializes a 3D pixel art coloring book on mobile devices. You can blow your stress away as you paint spaces in the order of numbers on the screen while reading calming messages. Relaxing background music you will listen during gameplay and its fairytale-like design will give you pleasure and happiness. You can download it for free on Google Play and the Apple App Store. (Graphic: Business Wire) Its Android and iOS versions were released at the same time so the users can download it for free on Google Play and the Apple App Store. My Coloring is a game that materializes a 3D pixel art col